Ciclopirox nail lacquer solution 8% in the 21st century
- PMID: 11051138
- DOI: 10.1067/mjd.2000.109068
Ciclopirox nail lacquer solution 8% in the 21st century
Abstract
Ciclopirox nail lacquer solution 8% has been shown to be effective in the treatment of dermatophyte onychomycosis of mild to moderate severity Other studies report the effectiveness of ciclopirox nail lacquer in onychomycosis caused by Candida sp and nondermatophyte molds. Ciclopirox nail lacquer may also be valuable in the treatment of early cases of reinfection/relapse. Ciclopirox nail lacquer solution 8% may be an important adjunct to oral antifungal therapy in certain presentations that might be poorly responsive to oral antifungal therapy alone (eg, lateral onychomycosis, longitudinal spike, dermatophytoma, and extensive onycholysis). In some cases, surgical therapies may need to be considered in addition to, or in preference to, topical nail lacquer treatment. The use of ciclopirox nail lacquer solution 8% as an adjunct to oral antifungal therapy may widen the spectrum of activity of the combination because of the broad spectrum of coverage provided by the lacquer. The use of combination therapy may be synergistic in terms of efficacy, enabling a reduction in the duration and cumulative dosage of oral therapy. This could result in a decrease in the frequency and severity of systemic adverse effects associated with the oral antimycotics and the need to be vigilant about drug interactions. Studies need to be conducted to determine the place of combination oral and topical lacquer therapy in the management of onychomycosis.
Similar articles
-
Ciclopirox nail lacquer: a brush with onychomycosis.Cutis. 2001 Aug;68(2 Suppl):13-6. Cutis. 2001. PMID: 11665723 Review.
-
Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S70-80. doi: 10.1067/mjd.2000.109071. J Am Acad Dermatol. 2000. PMID: 11051136
-
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S81-95. doi: 10.1067/mjd.2000.109069. J Am Acad Dermatol. 2000. PMID: 11051137
-
Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S57-69. doi: 10.1067/mjd.2000.109072. J Am Acad Dermatol. 2000. PMID: 11051135 Review.
-
Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.J Am Podiatr Med Assoc. 2007 May-Jun;97(3):195-202. doi: 10.7547/0970195. J Am Podiatr Med Assoc. 2007. PMID: 17507527 Clinical Trial.
Cited by
-
Dermatophytomas: Clinical Overview and Treatment.J Fungi (Basel). 2022 Jul 19;8(7):742. doi: 10.3390/jof8070742. J Fungi (Basel). 2022. PMID: 35887497 Free PMC article. Review.
-
Onychodystrophy and its management.Ger Med Sci. 2003 Jul 1;1:Doc02. Ger Med Sci. 2003. PMID: 19675700 Free PMC article.
-
Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.Oncotarget. 2017 Dec 8;9(12):10360-10374. doi: 10.18632/oncotarget.23164. eCollection 2018 Feb 13. Oncotarget. 2017. PMID: 29535812 Free PMC article.
-
Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.Infect Drug Resist. 2024 Mar 4;17:819-843. doi: 10.2147/IDR.S431526. eCollection 2024. Infect Drug Resist. 2024. PMID: 38463386 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources